Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
Condition: Hypertension
MeSH terms: Hypertension
Intervention: Candesartan cilexetil; Hydrochlorothiazide; Candesartan/HCT 32/25 mg
Intervention description: 32 mg oral tablet; 25 mg oral tablet
Intervention MeSH terms: Hydrochlorothiazide; Candesartan; Candesartan cilexetil
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 2207.0
Sex: All
Minimum age: 20 Years
Maximum age: 80 Years
Healthy volunteers: No
Keywords: Blood pressure reduction; combination therapy; candesartan cilexetil; hydrochlorothiazide

Summary:

      The aim is to compare the blood pressure lowering effect of the combination of candesartan
      cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32
      mg alone, HCT 25 mg alone and placebo in hypertensive adults.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be eligible for enrolment into the study (Visit 1) if they fulfil all of
             the following criteria:

          -  Provision of signed Informed Consent

          -  Primary hypertension, untreated or treated with a maximum of 2 antihypertensive drugs
             (substances), which the patient and the physician are willing to withdraw at enrolment
             and replace with placebo.

          -  Mean sitting DBP 90-114 mmHg (value calculated in the eCRF) at Visits 1 and 2

          -  Patients will be eligible for randomisation (Visit 4) if they fulfil the following
             criterion:

          -  Mean sitting DBP of 90-114 mmHg (value calculated in the eCRF) at the end of the
             4-week single-blind placebo run-in period. The run-in period should not be shorter
             than 4 weeks.

        Exclusion Criteria:

          -  Pregnant or lactating women, or women of childbearing potential not practising an
             adequate method of contraception eg, intrauterine device, oral contraception or
             progesterone implant. Pregnancy must be excluded by a negative pregnancy test at Visit
             1.

          -  Secondary or malignant hypertension

          -  Sitting SBP of 180 mmHg or more

          -  Myocardial infarction, stroke, coronary bypass surgery or transient ischaemic attack
             within 6 months before enrolment

          -  Angina pectoris requiring more treatment than short-acting nitrates

          -  Chronic use of NSAIDs

          -  Aortic or mitral valve stenosis

          -  Cardiac failure requiring treatment

          -  Cardiac arrhythmia requiring treatment

          -  Gout

          -  Renal artery stenosis or kidney transplantation

          -  Intravascular volume depletion

          -  Hypersensitivity to any component of the investigational products or to any
             sulphonamide derived drugs

          -  Concomitant disease which may interfere with the assessment of the patient

          -  Past or present alcohol or drug abuse, or any condition associated with poor
             compliance that in the opinion of the investigator might affect the patient's
             participation in the study

          -  Chronic liver disease

          -  Concomitant or previous treatment with any other investigational drug within 20 days
             of enrolment

          -  Previous enrolment in the present study